JNJ JOHNSON & JOHNSON

NYSE jnj.com


$ 191.14 $ 0.32 (0.17 %)    

Wednesday, 15-Oct-2025 19:30:39 EDT
QQQ $ 602.18 $ 4.22 (0.71 %)
DIA $ 463.02 $ 0.00 (0 %)
SPY $ 664.78 $ 2.94 (0.44 %)
TLT $ 90.75 $ -0.20 (-0.22 %)
GLD $ 387.00 $ 6.60 (1.73 %)
$ 191.17
$ 191.48
$ 190.75 x 1
$ 191.15 x 80
$ 189.30 - $ 193.57
$ 137.37 - $ 194.40
9,328,087
na
460.4B
$ 0.33
$ 20.32
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-24-2025 06-29-2025 10-Q
2 04-23-2025 03-30-2025 10-Q
3 02-13-2025 12-29-2024 10-K
4 10-23-2024 09-29-2024 10-Q
5 07-25-2024 06-30-2024 10-Q
6 05-01-2024 03-31-2024 10-Q
7 02-16-2024 12-31-2023 10-K
8 10-27-2023 10-01-2023 10-Q
9 10-27-2023 10-01-2023 10-Q
10 07-31-2023 07-02-2023 10-Q
11 04-28-2023 04-02-2023 10-Q
12 02-16-2023 01-01-2023 10-K
13 10-27-2022 10-02-2022 10-Q
14 07-29-2022 07-03-2022 10-Q
15 04-29-2022 04-03-2022 10-Q
16 02-17-2022 01-02-2022 10-K
17 10-29-2021 10-03-2021 10-Q
18 07-29-2021 07-04-2021 10-Q
19 04-30-2021 04-04-2021 10-Q
20 02-22-2021 01-03-2021 10-K
21 10-23-2020 09-27-2020 10-Q
22 07-24-2020 06-28-2020 10-Q
23 04-29-2020 03-29-2020 10-Q
24 02-18-2020 12-29-2019 10-K
25 10-28-2019 09-29-2019 10-Q
26 07-29-2019 06-30-2019 10-Q
27 05-01-2019 03-31-2019 10-Q
28 02-20-2019 12-30-2018 10-K
29 10-31-2018 09-30-2018 10-Q
30 08-02-2018 07-01-2018 10-Q
31 05-01-2018 04-01-2018 10-Q
32 02-21-2018 12-31-2017 10-K
33 11-02-2017 10-01-2017 10-Q
34 08-03-2017 07-02-2017 10-Q
35 05-08-2017 04-02-2017 10-Q
36 02-27-2017 01-01-2017 10-K
37 11-04-2016 10-02-2016 10-Q
38 08-04-2016 07-03-2016 10-Q
39 05-10-2016 04-03-2016 10-Q
40 02-24-2016 01-03-2016 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 johnson--johnson-rules-out-big-acquisitions-reiterates-focus-on-small-deals-analyst

Johnson & Johnson raised its 2025 revenue guidance as Stelara erosion slowed, while BofA maintained a Neutral rating citing...

 citigroup-maintains-buy-on-johnson--johnson-raises-price-target-to-215

Citigroup analyst Joanne Wuensch maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $213...

 stifel-maintains-hold-on-johnson--johnson-raises-price-target-to-190

Stifel analyst Rick Wise maintains Johnson & Johnson (NYSE:JNJ) with a Hold and raises the price target from $165 to $190.

 raymond-james-maintains-outperform-on-johnson--johnson-raises-price-target-to-209

Raymond James analyst Jayson Bedford maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and raises the price targe...

 morgan-stanley-maintains-equal-weight-on-johnson--johnson-raises-price-target-to-190

Morgan Stanley analyst Terence Flynn maintains Johnson & Johnson (NYSE:JNJ) with a Equal-Weight and raises the price tar...

 b-of-a-securities-maintains-neutral-on-johnson--johnson-raises-price-target-to-204

B of A Securities analyst Tim Anderson maintains Johnson & Johnson (NYSE:JNJ) with a Neutral and raises the price target...

 ubs-maintains-buy-on-johnson--johnson-raises-price-target-to-214

UBS analyst Danielle Antalffy maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $190 to...

 johnson--johnson-cfo-joseph-wolk-says-2026-adj-eps-expected-to-exceed-current-street-estimates-by-as-much-as-5-cents

- Conf Call

 johnson--johnson-cfo-joseph-wolk-says-expect-rulings-on-certain-legal-motions-pending-in-talc-litigation-by-q1-2026-says-2026-revenue-growth-in-total-expected-to-exceed-5-above-current-street-estimates

- Conf Call

 johnson--johnson-to-separate-orthopedics-business-boosts-annual-sales-outlook

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthoped...

 stock-market-today-dow-jones-nasdaq-futures-tumble-ahead-of-big-bank-earningsgoldman-sachs-jpmorgan-citigroup-in-focus-updated

Editor’s Note: The future prices of benchmark tracking ETFs, the lede, and the latest economic releases were updated in the sto...

 johnson--johnson-intends-to-separate-its-orthopedics-business-and-establish-a-standalone-business-operating-as-depuy-synthes

Strengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segme...

 johnson--johnson-affirms-fy2025-adj-eps-guidance-of-1080-1090-vs-1087-est-raises-fy2025-sales-guidance-from-93200b-93600b-to-93500b-93900b-vs-93436b-est

($ in Billions, except EPS)October 2025July 2025Adjusted Operational Sales1,2,5Change vs. Prior Year / Mid-point3.5% – 4.0% / 3...

 goldman-sachs-jpmorgan-chase-and-3-stocks-to-watch-heading-into-tuesday

US stock futures lower, focus on Goldman Sachs, JPMorgan, Polaris, Johnson & Johnson, and Citigroup earnings.

 atai-life-sciences-remains-undervalued-analyst-initiates-with-around-125-stock-upside

Atai Life Sciences' BPL-003 shows strong Phase 2b results for treatment-resistant depression, with potential $2.5 billion s...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION